{"success":true,"data":{"pressRelease":{"id":"135794","rtpr_id":"nGNX8b8Tb7-20260904","ticker":"ONWD","exchange":"","all_tickers":["ONWD"],"title":"ONWARD Medical to Announce First-Half 2026 Results on September 9, 2026","author":"Globe Newswire","published_at":"2026-09-04T05:30:00.110Z","article_body":"EINDHOVEN, the Netherlands, Sept. 04, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical\nN.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company\npioneering therapies to restore movement, function, and independence in people\nwith spinal cord injury and other movement disabilities, today announced that\nit will release its first-half 2026 financial results and host a webcast with\na comprehensive business update on September 9, 2026.\n\nThe webcast, presented by CEO Dave Marver, will begin at 2:00 p.m. CEST / 8:00\na.m. EDT. To join, please register using this link\n(https://www.globenewswire.com/Tracker?data=RvqdfGCiOhiaWIyMc-GsE2W9nrj238oazr4FKSvC_Z5iPkkdxeDkNajoyV2QwW9MJqq_1v5xl0mvRQLnNqsfnd85OT790ss2MgP5ppuP9IprsDPS29dPSFkDrVp7FGN8cOh-EnLvkcsGVbQfWENeVszlpotJ61wzav8ljTP839SjYe4euol9sL-hyE25IeF9x-taie_nbEa81vVx1ISwPgDDMI7lfzfCAkc1f_ioGRwZNuXYtiznAiB3P40j2_YNG8I9pt71oD-Xpy3oWCUIS_pDl41xOeSnEOaFhPIiUvbf2WV1EGQo6gI3P_4CW1-jgMijKaatkw2emyHvePfug66OPIVBhTzHKDGuPXtXcZVE1poB6GU4SaNQUnBZvEeTnfNxNnjcha3fdpnG2u44EoG4eiUYRKTjrUd_3IZJMWrfyf4FPys3v5ui5v7su0axEwv0Bfpb1cbxhXiohGAf2RCNK4YW8BrJ86Vgx0owaTIMj4QIVq2xnTnD7fdp5Rh7MfgDFHwsQmkfw_YK4PwHbPi-fHVSfOu_ANi3gC5t5h2B_f__BpLuxopMF2Ly3C9q8N1uPSXmpxgNQPReMJpmluFJ8iqR6sVTjkoj8jeGC-0zUp2WK3_967Q5W70YC6XQ).\nA replay of the webcast and supporting materials will be available at\nir.onwd.com\n(https://www.globenewswire.com/Tracker?data=ydD6fE3HlI59GSUNghIC40GJdrBKLb7tpw6jNgJFuGVdMNr-4CTiETeFH_Vo-w1kCD7G0EiD5r-9D9KadZtWnA==).\n\nAbout ONWARD Medical\n\nONWARD Medical is the leading neurotechnology company pioneering therapies to\nrestore movement, function, and independence in people with spinal cord\ninjuries (SCI) and other movement disabilities. Building on decades of\nscientific discovery, preclinical research, and clinical studies conducted at\nleading hospitals, rehabilitation clinics, and neuroscience laboratories, the\nCompany developed its proprietary ARC Therapy. It has subsequently been\nawarded 10 Breakthrough Device Designations from the FDA. The Company’s\nARC-EX(®) System is cleared for commercial sale in the US and Europe. The\nCompany is also developing an investigational implantable system called\nARC-IM(®), designed to address several unmet needs including blood pressure\ninstability after spinal cord injury. It can also be paired with a\nbrain-computer interface (BCI) and artificial intelligence (AI) to restore\nthought-driven movement.\n\nHeadquartered in the Netherlands, the Company has a Science and Engineering\nCenter in Switzerland and a US office in Boston, Massachusetts. The Company is\nlisted on Euronext Paris, Brussels, and Amsterdam (ticker: ONWD), and its US\nADRs can be traded on OTCQX (ticker: ONWRY).\n\nTo learn more about ONWARD Medical’s commitment to partnering with the\nspinal cord injury community to develop innovative solutions for restoring\nmovement, function, and independence after spinal cord injury, please visit\nONWD.com\n(https://www.globenewswire.com/Tracker?data=hDH7KLzcU8nYq0ZoBHUBHaTz5Z28jq95tMrtmcXraddKdpPcGZwvhky0tnqbZRyrD_MwTIKsnJzsQDaflJ_HFw==).\n\nTo be kept informed about the Company’s technologies, research studies, and\nthe availability of therapies in your area, please complete this webform\n(https://www.globenewswire.com/Tracker?data=mZpljNoICXeHuqJzCfyt4faU1YUk72hNb10F061OElRaPt-Z6eUGiPee8xtKZL7L5NrYGBflTpYhwHLe40u3jD73w9s6P0HLOreG0Ff5WsI=).\n\nFor Media Inquiries: \nSébastien Cros, VP Communications \nmedia@onwd.com  \n\nFor Investor Inquiries: \ninvestors@onwd.com\n\nDisclaimer  \n\nCertain statements, beliefs, and opinions in this press release are\nforward-looking, which reflect the Company’s or, as appropriate, the Company\ndirectors’ current expectations and projections about future events. By\ntheir nature, forward-looking statements involve several risks, uncertainties,\nand assumptions that could cause actual results or events to differ materially\nfrom those expressed or implied by the forward-looking statements. These\nrisks, uncertainties, and assumptions could adversely affect the outcome and\nfinancial effects of the plans and events described herein. A multitude of\nfactors including, but not limited to, delays in regulatory approvals, changes\nin demand, competition, and technology, can cause actual events, performance,\nor results to differ significantly from any anticipated development.\nForward-looking statements contained in this press release regarding past\ntrends or activities should not be taken as a representation that such trends\nor activities will continue in the future. As a result, the Company expressly\ndisclaims any obligation or undertaking to release any update or revisions to\nany forward-looking statements in this press release as a result of any change\nin expectations or any change in events, conditions, assumptions, or\ncircumstances on which these forward-looking statements are based. Neither the\nCompany nor its advisers or representatives nor any of its subsidiary\nundertakings or any such person’s officers or employees guarantees that the\nassumptions underlying such forward-looking statements are free from errors\nnor does either accept any responsibility for the future accuracy of the\nforward-looking statements contained in this press release or the actual\noccurrence of the forecasted developments. You should not place undue reliance\non forward-looking statements, which speak only as of the date of this press\nrelease.\n\nTrademarks: ONWARD, ARC-EX, ARC-IM, ARC-BCI, and the stylized O-Logo are\nproprietary and registered trademarks of ONWARD Medical. Unauthorized use is\nstrictly prohibited.\n\nInvestigational Products: ARC-IM and ARC-BCI are investigational and not\navailable for commercial use. ARC-IM is limited by United States law to\ninvestigational use.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/a60261ec-0c66-4acb-8726-e567073990a2)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX8b8Tb7-20260904","title":"ONWARD Medical to Announce First-Half 2026 Results on September 9, 2026","author":"Globe Newswire","ticker":"ONWD","created":"2026-09-04T05:30:00.110Z","tickers":["ONWD"],"exchange":"","article_body":"EINDHOVEN, the Netherlands, Sept. 04, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical\nN.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company\npioneering therapies to restore movement, function, and independence in people\nwith spinal cord injury and other movement disabilities, today announced that\nit will release its first-half 2026 financial results and host a webcast with\na comprehensive business update on September 9, 2026.\n\nThe webcast, presented by CEO Dave Marver, will begin at 2:00 p.m. CEST / 8:00\na.m. EDT. To join, please register using this link\n(https://www.globenewswire.com/Tracker?data=RvqdfGCiOhiaWIyMc-GsE2W9nrj238oazr4FKSvC_Z5iPkkdxeDkNajoyV2QwW9MJqq_1v5xl0mvRQLnNqsfnd85OT790ss2MgP5ppuP9IprsDPS29dPSFkDrVp7FGN8cOh-EnLvkcsGVbQfWENeVszlpotJ61wzav8ljTP839SjYe4euol9sL-hyE25IeF9x-taie_nbEa81vVx1ISwPgDDMI7lfzfCAkc1f_ioGRwZNuXYtiznAiB3P40j2_YNG8I9pt71oD-Xpy3oWCUIS_pDl41xOeSnEOaFhPIiUvbf2WV1EGQo6gI3P_4CW1-jgMijKaatkw2emyHvePfug66OPIVBhTzHKDGuPXtXcZVE1poB6GU4SaNQUnBZvEeTnfNxNnjcha3fdpnG2u44EoG4eiUYRKTjrUd_3IZJMWrfyf4FPys3v5ui5v7su0axEwv0Bfpb1cbxhXiohGAf2RCNK4YW8BrJ86Vgx0owaTIMj4QIVq2xnTnD7fdp5Rh7MfgDFHwsQmkfw_YK4PwHbPi-fHVSfOu_ANi3gC5t5h2B_f__BpLuxopMF2Ly3C9q8N1uPSXmpxgNQPReMJpmluFJ8iqR6sVTjkoj8jeGC-0zUp2WK3_967Q5W70YC6XQ).\nA replay of the webcast and supporting materials will be available at\nir.onwd.com\n(https://www.globenewswire.com/Tracker?data=ydD6fE3HlI59GSUNghIC40GJdrBKLb7tpw6jNgJFuGVdMNr-4CTiETeFH_Vo-w1kCD7G0EiD5r-9D9KadZtWnA==).\n\nAbout ONWARD Medical\n\nONWARD Medical is the leading neurotechnology company pioneering therapies to\nrestore movement, function, and independence in people with spinal cord\ninjuries (SCI) and other movement disabilities. Building on decades of\nscientific discovery, preclinical research, and clinical studies conducted at\nleading hospitals, rehabilitation clinics, and neuroscience laboratories, the\nCompany developed its proprietary ARC Therapy. It has subsequently been\nawarded 10 Breakthrough Device Designations from the FDA. The Company’s\nARC-EX(®) System is cleared for commercial sale in the US and Europe. The\nCompany is also developing an investigational implantable system called\nARC-IM(®), designed to address several unmet needs including blood pressure\ninstability after spinal cord injury. It can also be paired with a\nbrain-computer interface (BCI) and artificial intelligence (AI) to restore\nthought-driven movement.\n\nHeadquartered in the Netherlands, the Company has a Science and Engineering\nCenter in Switzerland and a US office in Boston, Massachusetts. The Company is\nlisted on Euronext Paris, Brussels, and Amsterdam (ticker: ONWD), and its US\nADRs can be traded on OTCQX (ticker: ONWRY).\n\nTo learn more about ONWARD Medical’s commitment to partnering with the\nspinal cord injury community to develop innovative solutions for restoring\nmovement, function, and independence after spinal cord injury, please visit\nONWD.com\n(https://www.globenewswire.com/Tracker?data=hDH7KLzcU8nYq0ZoBHUBHaTz5Z28jq95tMrtmcXraddKdpPcGZwvhky0tnqbZRyrD_MwTIKsnJzsQDaflJ_HFw==).\n\nTo be kept informed about the Company’s technologies, research studies, and\nthe availability of therapies in your area, please complete this webform\n(https://www.globenewswire.com/Tracker?data=mZpljNoICXeHuqJzCfyt4faU1YUk72hNb10F061OElRaPt-Z6eUGiPee8xtKZL7L5NrYGBflTpYhwHLe40u3jD73w9s6P0HLOreG0Ff5WsI=).\n\nFor Media Inquiries: \nSébastien Cros, VP Communications \nmedia@onwd.com  \n\nFor Investor Inquiries: \ninvestors@onwd.com\n\nDisclaimer  \n\nCertain statements, beliefs, and opinions in this press release are\nforward-looking, which reflect the Company’s or, as appropriate, the Company\ndirectors’ current expectations and projections about future events. By\ntheir nature, forward-looking statements involve several risks, uncertainties,\nand assumptions that could cause actual results or events to differ materially\nfrom those expressed or implied by the forward-looking statements. These\nrisks, uncertainties, and assumptions could adversely affect the outcome and\nfinancial effects of the plans and events described herein. A multitude of\nfactors including, but not limited to, delays in regulatory approvals, changes\nin demand, competition, and technology, can cause actual events, performance,\nor results to differ significantly from any anticipated development.\nForward-looking statements contained in this press release regarding past\ntrends or activities should not be taken as a representation that such trends\nor activities will continue in the future. As a result, the Company expressly\ndisclaims any obligation or undertaking to release any update or revisions to\nany forward-looking statements in this press release as a result of any change\nin expectations or any change in events, conditions, assumptions, or\ncircumstances on which these forward-looking statements are based. Neither the\nCompany nor its advisers or representatives nor any of its subsidiary\nundertakings or any such person’s officers or employees guarantees that the\nassumptions underlying such forward-looking statements are free from errors\nnor does either accept any responsibility for the future accuracy of the\nforward-looking statements contained in this press release or the actual\noccurrence of the forecasted developments. You should not place undue reliance\non forward-looking statements, which speak only as of the date of this press\nrelease.\n\nTrademarks: ONWARD, ARC-EX, ARC-IM, ARC-BCI, and the stylized O-Logo are\nproprietary and registered trademarks of ONWARD Medical. Unauthorized use is\nstrictly prohibited.\n\nInvestigational Products: ARC-IM and ARC-BCI are investigational and not\navailable for commercial use. ARC-IM is limited by United States law to\ninvestigational use.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/a60261ec-0c66-4acb-8726-e567073990a2)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-04T05:30:00.156886058Z","server_sent_at_ms":1788499800156},"received_at":"2026-09-04T05:30:00.216Z","source_url":null},"analysis":{"id":"124674","press_release_id":"135794","analysis_json":{"industry":{"label":"Health Care Equipment","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"ONWARD Medical will release its first-half 2026 financial results and host a webcast with a comprehensive business update on September 9, 2026.\n\nThe webcast will be presented by CEO Dave Marver, beginning at 2:00 p.m. CEST / 8:00 a.m. EDT, with a replay and supporting materials available at ir.onwd.com.\n\nThis release is a scheduling notice only — no financial figures, trial data, or guidance appear in it — so investors focused on the ARC-EX commercial rollout and the ARC-IM / ARC-BCI pipeline should treat September 9 as the actual catalyst date.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Calendar reminder: ONWD H1-2026 results and business update webcast on Sept 9 at 2 p.m. CEST — no new data in this notice."},"keyFigures":{"customDimensions":{"webcast_time":"2:00 p.m. CEST / 8:00 a.m. EDT","earnings_release_date":"September 9, 2026"}},"namedEntities":{"people":[{"name":"Dave Marver","role":"CEO"},{"name":"Sébastien Cros","role":"VP Communications"}],"products":["ARC Therapy","ARC-EX System","ARC-IM","ARC-BCI"],"companies":[{"name":"ONWARD Medical N.V.","ticker":"ONWD","relationship":"issuer/filer"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"This is a routine scheduling notice for upcoming first-half 2026 results; it contains no financial figures, guidance, corporate actions, or new business data. Purely a calendar item."},"tickerRelevance":{"others":[{"ticker":"ONWRY","relevance":"US ADR of the same issuer, traded on OTCQX"}],"primary":"ONWD"},"globalImportance":12,"audienceRelevance":12,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"calendar-notice-only","sectorWeight":"neurotech-medtech","issuerAuthored":true,"householdBrandBoost":false}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"ONWARD Medical will release its first-half 2026 financial results and host a webcast with a comprehensive business update on September 9, 2026.\n\nThe webcast will be presented by CEO Dave Marver, beginning at 2:00 p.m. CEST / 8:00 a.m. EDT, with a replay and supporting materials available at ir.onwd.com.\n\nThis release is a scheduling notice only — no financial figures, trial data, or guidance appear in it — so investors focused on the ARC-EX commercial rollout and the ARC-IM / ARC-BCI pipeline should treat September 9 as the actual catalyst date.","key_figures":{"customDimensions":{"webcast_time":"2:00 p.m. CEST / 8:00 a.m. EDT","earnings_release_date":"September 9, 2026"}},"named_entities":{"people":[{"name":"Dave Marver","role":"CEO"},{"name":"Sébastien Cros","role":"VP Communications"}],"products":["ARC Therapy","ARC-EX System","ARC-IM","ARC-BCI"],"companies":[{"name":"ONWARD Medical N.V.","ticker":"ONWD","relationship":"issuer/filer"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-04T05:31:03.659Z","global_importance":12,"audience_relevance":12,"importance_components":{"tickerTier":"small-cap","eventGravity":"calendar-notice-only","sectorWeight":"neurotech-medtech","issuerAuthored":true,"householdBrandBoost":false}},"durationMs":63432,"modelName":"glm-4.7"}}